Johnson & Johnson

Johnson & Johnson is an American multinational healthcare and life sciences corporation founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Headquartered in New Brunswick, New Jersey, the company is publicly traded on the NYSE under the ticker JNJ. While a global entity employing over 130,000 people worldwide, it maintains a deep footprint in the Israeli technology and medical device sectors. A major recent corporate event was the 2023 spinoff of its consumer health division into an independent public company, Kenvue, focusing J&J strictly on pharmaceuticals and medical technologies.

The company operates through two primary divisions: Innovative Medicine (formerly Janssen Pharmaceuticals) and MedTech. The MedTech division develops devices for orthopedics, surgery, interventional solutions, and vision. In the Israeli ecosystem, the focus is predominantly on cardiovascular electrophysiology, surgical sealants, and biotechnology, solving highly specific clinical problems like cardiac arrhythmia mapping and surgical hemostasis. These products are sold to hospitals, clinics, and specialist physicians worldwide.

Johnson & Johnson holds a significant R&D and manufacturing presence in Israel, employing over 1,000 people locally. The cornerstone of its Israeli MedTech operations is Biosense Webster, originally an Israeli startup acquired in 1997, which develops the CARTO 3D cardiac mapping system with major R&D facilities in Yokneam and Haifa. J&J also operates Omrix Biopharmaceuticals, acquired in 2008, which develops biological surgical sealants with facilities in Jerusalem and Tel Hashomer. The company actively invests in the local ecosystem through its corporate venture arm, JJDC. In 2024, Johnson & Johnson expanded its local footprint by acquiring the Israeli medical device company V-Wave, which develops treatments for heart failure, for an upfront payment of $600 million and potential milestone payments up to $1.1 billion.